The Definitive Guide to Milademetan
All enrolled sufferers who gained no less than just one dose of zosuquidar or placebo through induction were monitored for your event of adverse situations (439 sufferers, 219 on zosuquidar and 210 on placebo). The most typical adverse gatherings were being linked to the period of prolonged and considerable myelosuppression as is anticipated with i